Redondo Francisco L, Bermudez Pilar, Cocco Claudio, Colella Francesca, Graziani Maria Stella, Fiehn Walter, Hierla Thomas, Lemoël Gisèle, Belliard AnneMarie, Manene Dieudonne, Meziani Mourad, Liebel Maryann, McQueen Matthew J, Stockmann Wolfgang
Hospital Central de la Cruz Roja, Madrid, Spain.
Clin Chem Lab Med. 2003 Mar;41(3):365-81. doi: 10.1515/CCLM.2003.058.
The new selective access analyser Cobas Integra 800 from Roche Diagnostics was evaluated in an international multicentre study at six sites. Routine simulation experiments showed good performance and full functionality of the instrument and provocation of anomalous situations generated no problems. The new features on Cobas Integra 800, namely clot detection and dispensing control, worked according to specifications. The imprecision of Cobas Integra 800 fulfilled the proposed quality specifications regarding imprecision of analytical systems for clinical chemistry with few exceptions. Claims for linearity, drift, and carry-over were all within the defined specifications, except urea linearity. Interference exists in some cases, as could be expected due to the chemistries applied. Accuracy met the proposed quality specifications, except in some special cases. Method comparisons with Cobas Integra 700 showed good agreement; comparisons with other analysis systems yielded in several cases explicable deviations. Practicability of Cobas Integra 800 met or exceeded the requirements for more than 95% of all attributes rated. The strong points of the new analysis system were reagent handling, long stability of calibration curves, high number of tests on board, compatibility of the sample carrier to other Roche systems, and the sample integrity check for more reliable analytical results. The improvement of the workflow offered by the 5-position rack and STAT handling like on Cobas Integra 800 makes the instrument attractive for further consolidation in the medium-sized laboratory, for dedicated use of special analytes, and/or as back-up in the large routine laboratory.
罗氏诊断公司新推出的选择性分析仪Cobas Integra 800在六个地点进行的一项国际多中心研究中得到了评估。常规模拟实验表明该仪器性能良好且功能齐全,引发异常情况时也未出现问题。Cobas Integra 800的新特性,即凝块检测和加样控制,均按规格运行。Cobas Integra 800的不精密度除少数例外情况外,均符合临床化学分析系统不精密度的拟议质量规格。线性、漂移和携带污染的指标均在规定范围内,尿素线性除外。由于所应用的化学方法,在某些情况下存在干扰。准确性除在某些特殊情况下外,均符合拟议的质量规格。与Cobas Integra 700的方法比较显示出良好的一致性;与其他分析系统的比较在一些情况下产生了可解释的偏差。Cobas Integra 800的实用性在所有评级属性中超过95%达到或超过了要求。新分析系统的优点包括试剂处理、校准曲线的长期稳定性、大量的检测项目、样品载体与其他罗氏系统的兼容性以及样品完整性检查以获得更可靠的分析结果。Cobas Integra 800上的5位样品架和急诊处理功能所带来的工作流程改进,使该仪器对于中型实验室进一步整合、专用特殊分析物以及/或作为大型常规实验室的备用仪器具有吸引力。